BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15983388)

  • 1. Intracellular signal transduction pathway proteins as targets for cancer therapy.
    Adjei AA; Hidalgo M
    J Clin Oncol; 2005 Aug; 23(23):5386-403. PubMed ID: 15983388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.
    Favoni RE; de Cupis A
    Pharmacol Rev; 2000 Jun; 52(2):179-206. PubMed ID: 10835099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel targets for cancer chemotherapy].
    Inoue S
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):191-201. PubMed ID: 8611047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
    Cohen SJ; Cohen RB; Meropol NJ
    J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule signal transduction inhibitors for the treatment of solid tumors.
    Leary A; Johnston SR
    Cancer Invest; 2007 Aug; 25(5):347-65. PubMed ID: 17661211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; CalabrĂ² L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
    Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
    Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.
    Lee AV; Schiff R; Cui X; Sachdev D; Yee D; Gilmore AP; Streuli CH; Oesterreich S; Hadsell DL
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):516S-23S. PubMed ID: 12538509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
    Mendoza FJ; Espino PS; Cann KL; Bristow N; McCrea K; Los M
    Arch Immunol Ther Exp (Warsz); 2005; 53(1):47-60. PubMed ID: 15761376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.
    Himpe E; Kooijman R
    Biofactors; 2009; 35(1):76-81. PubMed ID: 19319849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Akt/PKB pathway: molecular target for cancer drug discovery.
    Cheng JQ; Lindsley CW; Cheng GZ; Yang H; Nicosia SV
    Oncogene; 2005 Nov; 24(50):7482-92. PubMed ID: 16288295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    Mikalsen T; Gerits N; Moens U
    Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.